Study of histopathologic parameters to define the prognosis of stage II colon cancer

No abstract is available for this paper.

• Publication year

  2019

• Venue

  International Journal of Colorectal Disease

• Publication date

  2019-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00384-019-03279-1PMID 30915540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta‐analysis

  2018cited by this paper
• Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer.

  2018cited by this paper
• CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification

  2017cited by this paper
• Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta‐Analysis

  2017cited by this paper
• Poorly Differentiated Clusters: Clinical Impact in Colorectal Cancer

  2017cited by this paper
• Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016

  2017cited by this paper
• CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

  2016cited by this paper
• Poorly differentiated clusters with larger extents have a greater impact on survival: a semi-quantitative pathological evaluation for 239 patients with non-mucinous pT2-3 colorectal carcinoma

  2015cited by this paper
• The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review.

  2015cited by this paper
• The number of metastatic lymph nodes exhibiting poorly differentiated clusters predicts survival in patients with pStage III colorectal cancer

  2015cited by this paper
• Tumour budding in colorectal cancer: what do we know and what can we do?

  2015cited by this paper
• Left-sided early-onset vs late-onset colorectal carcinoma: histologic, clinical, and molecular differences.

  2015cited by this paper
• Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

  2015cited by this paper
• Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

  2015cited by this paper
• Should the grading of colorectal adenocarcinoma include microsatellite instability status?

  2014cited by this paper
• Histologic Categorization of Fibrotic Cancer Stroma in the Primary Tumor Is an Independent Prognostic Index in Resectable Colorectal Liver Metastasis

  2014cited by this paper
• Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2013cited by this paper
• New Criteria for Histologic Grading of Colorectal Cancer

  2012cited by this paper
• Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer

  2012cited by this paper
• Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

  2011cited by this paper
• Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

  2011cited by this paper
• DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

  2011cited by this paper
• Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

  2011cited by this paper
• Proposed objective criteria for "grade 3" in early invasive colorectal cancer.

  2010cited by this paper
• Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

  2010cited by this paper
• Tumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer

  2009cited by this paper
• Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

  2007cited by this paper
• Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.

  2007cited by this paper
• Population‐based study of prognostic factors in stage II colonic cancer

  2006cited by this paper
• Risk factors for an adverse outcome in early invasive colorectal carcinoma.

  2004cited by this paper
• Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

  2003cited by this paper
• Tumor Budding at the Invasive Margin Can Predict Patients at High Risk of Recurrence After Curative Surgery for Stage II, T3 Colon Cancer

  2003cited by this paper
• Tumour `budding' as an index to estimate the potential of aggressiveness in rectal cancer

  2002cited by this paper
• High‐risk groups of patients with Stage II colon carcinoma

  2001cited by this paper
• Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

  2000cited by this paper
• Observer variation in the histological grading of rectal carcinoma.

  1983cited by this paper

• Society of surgical oncology medical student & trainee primer for non-HPB GI oncology

  2026cites this paper
• Relative MYC downregulation and RUNX2 upregulation orchestrate partial epithelial‐mesenchymal transition in colorectal cancer tumor budding and poorly differentiated clusters

  2026cites this paper
• Independent prognostic significance of tumor budding and poorly differentiated clusters in Brazilian patients with stage II colorectal cancer

  2025cites this paper
• Clinical and immunopathological evaluation and its comparison with IHC consensus molecular subtypes of colorectal cancer

  2025cites this paper
• Microsatellite Status, Tumor Budding, CD3 and CD8 T Cell Densities in Relation to Invasiveness, Lymph Node Involvement in Colorectal Adenocarcinoma.

  2025cites this paper
• Comparison of the prognosis and lymph node metastasis between no tumor budding and low-grade tumor budding in T1 and T2 colorectal cancer

  2025cites this paper
• Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital

  2025influential citation
• Differentiation grade is highly concordant between matched primary and metastatic colorectal cancer

  2025cites this paper
• The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening program.

  2024cites this paper
• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

  2024cites this paper
• Correlations of pathomorphological parameters between lesions at the invasive front and lymph node metastases in colorectal cancer: a retrospective clinical study

  2024cites this paper
• Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.

  2024cites this paper
• Effects of tumour budding on adjuvant chemotherapy in colorectal cancer

  2024cites this paper
• Pseudobudding: ruptured glands do not represent true tumor buds

  2023cites this paper
• Is there no need to discuss adjuvant chemotherapy in stage II colon cancer patients with high tumor budding and lymphovascular invasion?

  2023cites this paper
• Prognostic Factors Among Colonic Adenocarcinomas Invading Into the Muscularis Propria

  2023cites this paper
• Facteurs histopronostiques et biomarqueurs pour une prise en charge personnalisée du cancer colorectal

  2023cites this paper
• Prognostic Value of Tumor Budding for Early Breast Cancer

  2023cites this paper
• Tumor Budding Assessment in Colorectal Carcinoma

  2023cites this paper
• Immunoexpression of Mismatch Repair Proteins in a Cohort of Colorectal Cancer Patients

  2023cites this paper
• Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

  2022cites this paper
• Multiple High-Risk Features for Stage II Colon Carcinoma Portends Worse Survival Than Stage III Disease

  2022cites this paper
• The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study

  2022cites this paper
• Scatter patterns in lymph node metastases as a novel prognostic indicator in patients with stage III/N2 colorectal cancer

  2021cites this paper
• Evaluation of Traditional Prognostic Factors for Stage I-III Colorectal Cancer Patients Who Survived for Over Five Years After Surgery

  2021cites this paper
• Refining the ITBCC tumor budding scoring system with a “zero-budding” category in colorectal cancer

  2021cites this paper
• Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer

  2021cites this paper
• The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer.

  2021cites this paper
• Ex Vivo Vibration Spectroscopic Analysis of Colorectal Polyps for the Early Diagnosis of Colorectal Carcinoma

  2021cites this paper
• Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II–III colon cancer

  2020cites this paper
• Poorly differentiated clusters in colorectal cancer: a current review and implications for future practice

  2020cites this paper
• Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients.

  2020cites this paper
• Prognostic role of aberrant mTOR activation in patients with stage II and III colorectal cancer.

  2020cites this paper
• Tumour budding in solid cancers

  2020cites this paper
• The presence of poorly differentiated clusters predicts survival in stage II colorectal cancer

  2020cites this paper
• Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer

  2019cites this paper